Join the Fluticasone / umeclidinium / vilanterol group to help and get support from people like you.
Fluticasone / umeclidinium / vilanterol News
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
FRIDAY, Jan. 3, 2025 – For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with...
FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of Asthma
London UK 9 September 2020 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy...
Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD
24 April 2018 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy...
FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
London UK – 18 September 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single i...
Further information
Related condition support groups
Chronic Obstructive Pulmonary Disease, Asthma